RT @matheos33: @PBasiukiewicz To ja dam takie: Leczenie nadciśnienia niekoniecznie się opłaca: https://t.co/WXHhxAap8U https://t.co/JR30BTJ…
@PBasiukiewicz To ja dam takie: Leczenie nadciśnienia niekoniecznie się opłaca: https://t.co/WXHhxAap8U https://t.co/JR30BTJKEk
@FLAHAULT Pas tout à fait... https://t.co/LG8UjVPbiB
@JesperKitos @dr_jon_l @LoebMimi @pkeetsbird @naomirwolf https://t.co/o4Tz6I6iHh Here’s an analysis of all the studies on which you authoritatively relied to place your patients on anti-hypertensives. They’re crap. And that shouldn’t surprise you.
@drjohnm Finding and interpret Cochrane's meta-analysis Such: https://t.co/FsjoL90J6P
RT @JuanGrvas: 3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no…
@MarkBensonMark @DrAseemMalhotra SBP of 135 would still have been ok IMO. We have to re-think hypertension. https://t.co/uFyFFEhbCE
@lowcarbGP @IntDiabetesFed @robbwolf @ESodicoffMD @Deprescribing @rcgp @APPG_Diabetes @ChooseWiselyCA @lowcarb_aus @grantsnz Your thoughts on treatment of mild hypertension? Many men so treated report erectile dysfunction & I’ve often wondered if it co
@bigfatsurprise 1. Possibly the most important aspect of blood pressure following weight loss concerns “mild essential hypertension” - a misnomer. Over past 40yrs I’ve seen 4 advices on hypertension- all of them wrong IMO. SBP < 160 is normal in aging a
Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) have not been shown to reduce mortality or morbidity in RCTs.https://t.co/atyP6UjT66
@florian_krammer In any case, unless you’re above 160 antihypertensives are a waste of time IMO. They are way over-prescribed, esp by Americans. It’s just one of those ideas that crept into practice in the 90s and has taken on a life of its own. https://t.
@TomPMarshall @thebyrdlab @calvapo @jordy_bc @hswapnil @f2harrell Link to meta-analysis here: https://t.co/w9N1t9opGi
@jordy_bc @thebyrdlab @calvapo @hswapnil Ample evidence for BP >140/90 with risk factors (CVD DM CKD PAD) or >160/100 Not for BP 140/90 to 159/99 without risk factors https://t.co/6CDSXgUe80
10/n Une revue Cochrane met en doute l'intérêt d'un tel traitement https://t.co/0trTacDCcE
RT @JuanGrvas: 3/ Cochrane: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic B…
RT @JuanGrvas: 3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no…
RT @JuanGrvas: 3/ Cochrane: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic B…
RT @JuanGrvas: 3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no…
RT @JuanGrvas: 3/ Cochrane: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic B…
RT @JuanGrvas: 3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no…
RT @JuanGrvas: 3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no…
RT @JuanGrvas: 3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no…
3/ Cochrane. Hipertensión leve (sistólica 140‐159 mmHg o diastólica 90‐99 mmHg) sin enfermedad cardiovascular. ¿Tratar o no tratar con medicamentos? NO TRATAR https://t.co/rFKON5P2aN
3/ Cochrane: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) have not been shown to reduce mortality or morbidity in RCTs. “ https://t.co/CPfHQ2yr
@Mido_5555555 @WHO Cochrane: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmHg and/or diastolic BP 90-99 mmHg) have not been shown to reduce mortality or morbidity in RCTs. “ http
15 Il existe en revanche une revue Cochrane datant de 2012, qui met en doute l’intérêt de traiter des patients non malades (en prévention primaire) même pour des PA>140 https://t.co/jBWSHeKk7F.
RT @Carcos2: "This prespecified analysis found no evidence to support guideline recommendations that encourage initiation of treatment in p…
"This prespecified analysis found no evidence to support guideline recommendations that encourage initiation of treatment in patients with low-risk mild hypertension. Evidence of an increased risk of adverse events". No es una novedad https://t.co/6hBNJgbt
@TheLancet How about this: https://t.co/bVk3yJopvF
@ResearchDPG Nice - this is source https://t.co/i5prK1R0zU But it seems to be an opinion paper with little new data ...
@thebyrdlab @raj_mehta @drandrewsharp But little evidence to support that *treatment* in mild hypertension with no comorbidities reduces the small risk compared with no treatment eg https://t.co/86NGpszzCU Agree that longer term benefit is plausible. But
@ScienceNews What to think about this? https://t.co/bVk3yJopvF
RT @hswapnil: @JJRyanMD No benefit in low risk: https://t.co/86NGpszzCU?amp=1 And why 130/80 in high risk rather than <120? Neither here n…
130 was a compromise. Since BP was measured unmonitored, the monitored BP reading would likely have been closer to 130 #ACCJournalClub https://t.co/kko3IUo1Vx
RT @kewatson: I also agree with this. That's the guidelines recommend nonpharmacologic therapy for low risk patients #ACCJournalClub https:…
Yes and it is patient's risk that should determine treatment. Remember this is part of the new guidelines of #HTN #ACCJournalClub https://t.co/w8BWeZs9Gi
I also agree with this. That's the guidelines recommend nonpharmacologic therapy for low risk patients #ACCJournalClub https://t.co/UW7LQeripi
@JJRyanMD No benefit in low risk: https://t.co/86NGpszzCU?amp=1 And why 130/80 in high risk rather than <120? Neither here nor there! #ACCJournalClub
@kewatson In low risk little evidence of BP lowering benefit to such low levels eg https://t.co/86NGpszzCU?amp=1 #ACCJournalClub @DrMarthaGulati
@thebyrdlab @michelaccad @ethanjweiss @HTNCanada Alright! Let me raise you to a @CochraneHTN SR of 11 RCTs https://t.co/86NGpszzCU & my defence is on behalf of this subgroup: https://t.co/FF0Pfc9pbr
RT @AVHernandezDiaz: No evidence support for new ACC/AHA HT guidelines https://t.co/fX43GLDNI7
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
@AnastasiaSMihai @MrWBond @michelaccad @RogueRad @Twitter @HTNCanada @ChristosArgyrop @DrMarthaGulati @mmamas1973 @ShehabAnwer @rladeiraslopes @DocSavageTJU @fischman_david But really, BP 122 in low CV risk is ‘elevated’? What’s the data to support inter
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
No evidence support for new ACC/AHA HT guidelines https://t.co/fX43GLDNI7
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
I suppose the new guidelines are a form of fake news, looking at this Cochrane review. We can press the BS button again Benefits of antihypertensive drugs for mild hypertension are unclear https://t.co/fyuFkALIs4
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @Farmahond: Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu k…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
Ondanks ontbreken hard bewijs is in VS richtlijn bloeddruk naar beneden bijgesteld: https://t.co/SV6hIjp0a7 Hoe zou dat nu komen?🤔 Tip: “Het AHA journaal is mede mogelijk gemaakt door financiële ondersteuning van Amgen en Novartis” https://t.co/TK58HOf3do
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
RT @DrAseemMalhotra: MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140…
MUST acknowledge @cochranecollab review revealed no hard outcome benefit in treating BP for low/mod risk in range 140 - 159 systolic or 90 - 99 diastolic! ( most people taking BP pills!) https://t.co/qqeaqEgby5 #choosingwisely #EBM https://t.co/vZYdKWN4wu
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
RT @JuanGrvas: @EricTopol @javierpadillab @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Cochrane: “Antihypertensive drugs used in…
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
@kazemr @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 https://t.co/NnyCeYpnv8 Not just @JAMAInternalMed Consistent with 2 @cochranecollab reviews cited and see https://t.co/4V64eLcKGa
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
RT @HHakeam: قبل المضي قدما وتبني توصيات AHA الجديدة, إمنح نفسك فرصة للإطلاع على رؤى أخرى https://t.co/V1tkZLP1HY
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
RT @DrAseemMalhotra: Yet another example of ‘science’ taking a turn towards darkness @richardhorton1. @cochranecollab review revealed Tx <1…
RT @HHakeam: قبل المضي قدما وتبني توصيات AHA الجديدة, إمنح نفسك فرصة للإطلاع على رؤى أخرى https://t.co/V1tkZLP1HY
RT @EricTopol: @JAMAInternalMed @American_Heart @ACCinTouch @jsross119 Adding the 2 relevant @cochranecollab systematic reviews. There is n…
RT @barttels2: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmH…
RT @JuanGrvas: Inyectando miedo a la hipertensión con falsedades. "Cuanto más baja mejor" "Incluso la antigua hipertensión moderada es una…
RT @HHakeam: قبل المضي قدما وتبني توصيات AHA الجديدة, إمنح نفسك فرصة للإطلاع على رؤى أخرى https://t.co/V1tkZLP1HY
RT @HHakeam: قبل المضي قدما وتبني توصيات AHA الجديدة, إمنح نفسك فرصة للإطلاع على رؤى أخرى https://t.co/V1tkZLP1HY
RT @DrAseemMalhotra: Yet another example of ‘science’ taking a turn towards darkness @richardhorton1. @cochranecollab review revealed Tx <1…
RT @barttels2: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmH…
RT @HHakeam: قبل المضي قدما وتبني توصيات AHA الجديدة, إمنح نفسك فرصة للإطلاع على رؤى أخرى https://t.co/V1tkZLP1HY
RT @barttels2: “Antihypertensive drugs used in the treatment of adults (primary prevention) with mild hypertension (systolic BP 140-159 mmH…